EXAS Stock Overview
Provides cancer screening and diagnostic test products in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Exact Sciences Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$44.57 |
52 Week High | US$100.77 |
52 Week Low | US$40.62 |
Beta | 1.22 |
11 Month Change | -2.15% |
3 Month Change | -36.54% |
1 Year Change | -50.79% |
33 Year Change | -62.77% |
5 Year Change | -61.20% |
Change since IPO | 202.17% |
Recent News & Updates
Exact Sciences: Still No Reason To Own
Jun 11Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02Recent updates
Exact Sciences: Still No Reason To Own
Jun 11Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued
Feb 23Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel
Jan 08Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate
Nov 15Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Oct 04An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued
Aug 14Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Jun 15Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)
Apr 26We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Feb 23An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued
Jan 10Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?
Oct 31Exact Sciences: Price Is Yet To Catch Up As Management Draws Profitability Plans
Oct 13Shareholder Returns
EXAS | US Biotechs | US Market | |
---|---|---|---|
7D | 5.5% | -2.3% | 1.0% |
1Y | -50.8% | 8.2% | 23.6% |
Return vs Industry: EXAS underperformed the US Biotechs industry which returned 8.2% over the past year.
Return vs Market: EXAS underperformed the US Market which returned 23.6% over the past year.
Price Volatility
EXAS volatility | |
---|---|
EXAS Average Weekly Movement | 7.4% |
Biotechs Industry Average Movement | 10.2% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: EXAS's share price has been volatile over the past 3 months.
Volatility Over Time: EXAS's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 6,550 | Kevin Conroy | www.exactsciences.com |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Exact Sciences Corporation Fundamentals Summary
EXAS fundamental statistics | |
---|---|
Market cap | US$7.97b |
Earnings (TTM) | -US$240.23m |
Revenue (TTM) | US$2.53b |
3.2x
P/S Ratio-34.2x
P/E RatioIs EXAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EXAS income statement (TTM) | |
---|---|
Revenue | US$2.53b |
Cost of Revenue | US$667.48m |
Gross Profit | US$1.87b |
Other Expenses | US$2.11b |
Earnings | -US$240.23m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.30 |
Gross Margin | 73.67% |
Net Profit Margin | -9.48% |
Debt/Equity Ratio | 75.5% |
How did EXAS perform over the long term?
See historical performance and comparison